Novo Holdings Completes $16.5 Billion Catalent Acquisition
Deal News | Dec 19, 2024 | Goodwin
Novo Holdings, wholly owned by the Novo Nordisk Foundation, has successfully completed its acquisition of Catalent, Inc. in an all-cash deal valued at approximately $16.5 billion. Novo Holdings is a prominent life sciences investor, managing a diversified investment portfolio with total assets of EUR 149 billion as of the end of 2023. The acquisition deal, led by a team from Goodwin's Private Equity and Public M&A groups, will enhance Novo Holdings' investment portfolio. As part of the acquisition strategy, Novo Holdings will divest three of Catalent's sites located in Italy, the USA, and Belgium to Novo Nordisk A/S. The deal underscores Novo Holdings' long-term investment strategy to generate attractive returns while focusing on improving health and sustainability globally. The legal and advisory teams involved represent substantial expertise from Goodwin, encompassing various aspects such as tax, intellectual property, privacy, and global trade.
Sectors
- Private Equity
- Life Sciences
- Pharmaceutical Manufacturing
- Legal Services
Geography
- Global – Novo Holdings operates globally, with this transaction affecting sites in Italy, the USA, and Belgium.
- Denmark – Novo Holdings is based in Denmark, making this a key geographic location for the article.
- United States – One of Catalent's sites to be sold is located in the USA, and the company itself is listed on the NYSE.
- Italy – One of Catalent's sites sold in the transaction is located in Anagni, Italy.
- Belgium – A Catalent site in Brussels, Belgium is also part of the transaction with Novo Nordisk.
Industry
- Private Equity – The article discusses Novo Holdings, a significant player in the private equity space, and its acquisition strategies.
- Life Sciences – The focus on Catalent, a company within the life sciences sector, and Novo Holdings' investment strategy in this area highlights the industry's relevance.
- Pharmaceutical Manufacturing – Catalent is involved in contract pharmaceutical development and manufacturing, making this industry classification pertinent.
- Legal Services – Goodwin, a law firm providing legal services for this transaction, contributes to this industry classification.
Financials
- 16.5 billion US dollars – The total enterprise value of the acquisition of Catalent by Novo Holdings.
- 149 billion EUR – The total assets managed by Novo Holdings as of year-end 2023.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Novo Holdings A/S | Acquirer | Company | An investment company owned by the Novo Nordisk Foundation, focusing on life sciences investments. |
| Catalent, Inc. | Target | Company | A global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. |
| Goodwin | Legal Advisor | Company | A law firm providing legal advice and services, particularly in private equity and public M&A. |
| Novo Nordisk A/S | Bidding Company | Company | A global healthcare company involved in the acquisition of Catalent's sites from Novo Holdings. |
| Novo Nordisk Foundation | Owner | Charity | An economic, scientific, and humanitarian foundation that owns Novo Holdings. |